Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2017-05-783274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cyclin D1-negative mantle cell lymphoma.
Hum Pathol
November 2024
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Cyclin D1-negative mantle cell lymphoma (MCL) is regarded as a B-cell neoplasm that has morphologic and immunophenotypic findings indistinguishable from typical MCL. These neoplasms lack cyclin D1 overexpression by immunohistochemistry and t(11;14)(q13;q32)/IGH::CCND1. Since cyclin D1-negative MCL was first recognized by gene expression profiling in 2003, there has been diagnostic confusion regarding this entity, mostly attributable to a lack of diagnostic tools to recognize these neoplasms in most clinical laboratories.
View Article and Find Full Text PDFCyclin D1 expression in penile cancer.
Oncotarget
May 2024
Postgraduate Program in Adult Health, Federal University of Maranhão, Maranhão, Brazil.
The main goal of the present study was to analyze the expression profile of cyclin D1 in patients with PC, and to determine possible correlations with clinical and histopathological features. A survey was conducted with 100 patients diagnosed with PC, who were treated at two reference hospitals in São Luís, Maranhão, Brazil, between 2013 and 2017. A review of clinical, epidemiological, and histopathological data was performed, Human Papillomavírus (HPV) DNA was detected using polymerase chain reaction (PCR) and cyclin D1 expression analysis was performed using immunohistochemical techniques.
View Article and Find Full Text PDFSOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Mod Pathol
February 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- A study of 13 SOX11+ large or blastoid B-cell neoplasms highlights the challenges in diagnosing these types of cancers, which may be confused with cyclin D1-negative mantle cell lymphoma (MCL) or other aggressive B-cell lymphomas.
- Fluorescence in situ hybridization showed no CCND1 rearrangements in the cases, with some instances of CCND2 alterations, while gene expression profiling indicated similarities to cyclin D1+ MCL but distinct differences from diffuse large B-cell lymphoma (DLBCL).
- The findings suggest that SOX11 is a reliable marker for diagnosing cyclin D1-negative blastoid/pleomorphic MCL, advocating for routine testing in B-cell neoplasms
Recent advances in genomics and therapeutics in mantle cell lymphoma.
Cancer Treat Rev
January 2024
Division of Hematopathology, Duke University Medical Center, Durham, NC 27710, USA; Duke Cancer Institute, Duke University, Durham, NC 27710, USA. Electronic address:
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolent and aggressive forms, is intricately linked to factors such as the mutational status of the variable region of the immunoglobulin heavy chain gene, epigenetic profiling, and Sox11 expression. Several intriguing subtypes of MCL, such as Cyclin D1-negative MCL, in situ mantle cell neoplasm, CCND1/IGH FISH-negative MCL, and the impact of karyotypic complexity on prognosis, have been explored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!